Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234038 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT01234038 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 116 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01234038, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG ISIS EIF4E Rx
Study Locations (20)
Other
- Koranyi National Institute of TBC and Pulmonology - Budapest
- Semmelweis University Faculty of Medicine - Budapest
- University of Debrecen, Medical and Health Science Center - Debrecen
- Hospital for Thoracic Diseases of Csongrad County Local Governmental - Deszk
- Bekes Country Pandy Kalman Hospital - Gyula
- K. Dluski Provincial Specialist Hospital - Bialystok
- Independent Public Teaching Hospital No. 4 In Lublin - Lublin
- Idependent Public Tuberculosis an Lung Diseases Facilities - Olsztyn
- Specialist Tuberculosis and Lung Diseases Hospitals - Rzeszów
- Alojzy Pawelec Provincial Hospital of Lung Diseases - Wodzisław Śląski
Arkansas
- Highlands Oncology Group - Fayetteville
- Genesis Cancer Center - Hot Springs
- Little Rock Cancer Clinic - Little Rock
Kentucky
- University of Louisville - James Graham Brown Cancer Center - Louisville
- Jewish Hospital & St. Mary's Healthcare - Louisville
Alabama
- Achieve Clinical Research - Birmingham
California
- Kenmar Research Institute - Los Angeles
Illinois
- Joliet Hematology Oncology Associates - Joliet
Ohio
- Gabrail Cancer Center - Canton
Texas
- Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234038
The ClinicalTrials.gov registry entry for NCT01234038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01234038 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Arkansas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01234038 about?
NCT01234038 is a clinical study titled "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel". The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
What is the current status of trial NCT01234038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2010-11. Estimated completion is 2013-01.
What conditions does trial NCT01234038 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT01234038?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), ISIS EIF4E Rx (DRUG).
Who is sponsoring clinical trial NCT01234038?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01234038 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.